Home > Publications Database > Chr:17q21.31 locus risk haplotype H1 susceptibility to ferroptosis is mediated by endolysosomal pathway. > print

001     282293
005     20251212103343.0
024 7 _ |a 10.1038/s41419-025-08147-1
|2 doi
024 7 _ |a pmid:41238560
|2 pmid
024 7 _ |a pmc:PMC12618564
|2 pmc
037 _ _ |a DZNE-2025-01263
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Sadikoglou, Eldem
|0 P:(DE-2719)9001460
|b 0
|e First author
245 _ _ |a Chr:17q21.31 locus risk haplotype H1 susceptibility to ferroptosis is mediated by endolysosomal pathway.
260 _ _ |a London [u.a.]
|c 2025
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765455260_17915
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Human chr:17q21.31 locus is a complex genomic region of high linkage disequilibrium with two main haplotypes, named H1 and H2. The H1 haplotype is genetically associated with a wide spectrum of neurodegenerative diseases (NDs), including tauopathies and synucleinopathies, with the underlying mechanism remaining unknown. We investigated the interplay of environmental and genetic risk factors on neurons derived from iPSCs of both haplotypes under Mild Chronic Oxidative Stress (MCOS) conditions. The observed increased susceptibility of H1 neurons to MCOS leading to an earlier neuronal death, was mediated by ferroptosis. Characterization of the phenotype revealed spatiotemporal propagation and spreading of axonal deterioration and neuronal death in accordance with NDs pathology. Transcriptional profiling pointed to ferroptosis hallmarks and endo-lysosomal vesicles as implicated pathways, while FDA-approved drugs prevented the induced death in H1 neurons. Finally, ROS and lysosomal dynamics during the neuronal maturation shed further light to the differential response of haplotypes to MCOS, which could explain the risk association of the H1 haplotype with NDs.
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 2
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Reactive Oxygen Species
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Lysosomes: metabolism
|2 MeSH
650 _ 2 |a Ferroptosis: genetics
|2 MeSH
650 _ 2 |a Haplotypes: genetics
|2 MeSH
650 _ 2 |a Neurons: metabolism
|2 MeSH
650 _ 2 |a Neurons: pathology
|2 MeSH
650 _ 2 |a Oxidative Stress
|2 MeSH
650 _ 2 |a Genetic Predisposition to Disease
|2 MeSH
650 _ 2 |a Endosomes: metabolism
|2 MeSH
650 _ 2 |a Induced Pluripotent Stem Cells: metabolism
|2 MeSH
650 _ 2 |a Reactive Oxygen Species: metabolism
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: genetics
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: pathology
|2 MeSH
700 1 _ |a Domingo-Fernández, Daniel
|b 1
700 1 _ |a Savytska, Natalia
|0 P:(DE-2719)2812754
|b 2
700 1 _ |a Fernandes, Noemia
|0 P:(DE-2719)2811866
|b 3
|u dzne
700 1 _ |a Rizzu, Patrizia
|0 P:(DE-2719)2810718
|b 4
700 1 _ |a Illarionova, Anastasia
|0 P:(DE-2719)2812762
|b 5
|u dzne
700 1 _ |a Strauß, Tabea
|0 P:(DE-2719)2811799
|b 6
700 1 _ |a Schwarz, Sigrid
|0 P:(DE-2719)2812262
|b 7
700 1 _ |a Kodamullil, Alpha
|b 8
700 1 _ |a Höglinger, Günter U
|0 P:(DE-2719)2811373
|b 9
|u dzne
700 1 _ |a Dhingra, Ashutosh
|0 P:(DE-2719)2811729
|b 10
|u dzne
700 1 _ |a Gasser, Thomas
|0 P:(DE-2719)2320009
|b 11
|u dzne
700 1 _ |a Heutink, Peter
|0 P:(DE-2719)2810728
|b 12
|e Last author
773 _ _ |a 10.1038/s41419-025-08147-1
|g Vol. 16, no. 1, p. 828
|0 PERI:(DE-600)2541626-1
|n 1
|p 828
|t Cell death & disease
|v 16
|y 2025
|x 2041-4889
856 4 _ |u https://pub.dzne.de/record/282293/files/DZNE-2025-01263%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/282293/files/DZNE-2025-01263.pdf
856 4 _ |u https://pub.dzne.de/record/282293/files/DZNE-2025-01263%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/282293/files/DZNE-2025-01263%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/282293/files/DZNE-2025-01263%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/282293/files/DZNE-2025-01263.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:282293
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001460
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2812754
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2811866
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810718
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2812762
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811799
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2812262
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2811373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2811729
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2320009
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2810728
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 2
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-01
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL DEATH DIS : 2022
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:36:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:36:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-01
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-01
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-01
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:36:07Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-01
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CELL DEATH DIS : 2022
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-01
920 1 _ |0 I:(DE-2719)1210002
|k AG Heutink
|l Genome Biology of Neurodegenerative Diseases
|x 0
920 1 _ |0 I:(DE-2719)1210013
|k AG Bansal
|l Biomedical Data Science
|x 1
920 1 _ |0 I:(DE-2719)1210009
|k AG Rizzu
|l Applied Genomics for Neurodegenerative Diseases
|x 2
920 1 _ |0 I:(DE-2719)1240005
|k ICRU
|l Core ICRU
|x 3
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 4
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 5
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210002
980 _ _ |a I:(DE-2719)1210013
980 _ _ |a I:(DE-2719)1210009
980 _ _ |a I:(DE-2719)1240005
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1210000
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21